Press Releases keyboard_arrow_down
Media Coverage keyboard_arrow_down
Events keyboard_arrow_down
Blog keyboard_arrow_down
Webinars keyboard_arrow_down
Brochures keyboard_arrow_down

Media Relations

Eloquest Healthcare Contacts

Matthew Stahl
Clinical Marketing & Brand Director


Vancive Contacts

Andrew Deckert
Global Marketing Communications Manager
+1 224 374 2109

Barbara Van Rymenam
Global Director, CHG Program
+32 (0)497 103233


Eloquest Healthcare and Avery Dennison Medical to Introduce New Post-Operative Dressings with CHG Antimicrobial

Eloquest Healthcare ReliaTect Post-Op dressings will be introduced at the AORN Global Surgical Conference & Expo in Boston, MA


FERNDALE, Mich., Mar. 30, 2017 – A line of transparent post-operative dressings designed to enhance patient care will be jointly introduced by Eloquest Healthcare®, Inc. and Avery Dennison Medical at AORN in Boston, MA. The device just received 510(k) clearance from the FDA.

The new dressings, called ReliaTect™, incorporate BeneHold™ CHG, an innovative adhesive technology from Avery Dennison Medical, that comfortably secures the dressing to the skin, absorbs fluids and protects the site from external contaminants. The CHG contained within the adhesive preserves the dressings from microbial growth, making them ideally suited for post-operative sites. Eloquest Healthcare is the exclusive distributor of the dressings in the United States and Canada.

“The unique characteristics of the ReliaTect post-operative dressings make them a great complement to our growing portfolio and increases the value we are able to provide to our customers.” said Tim O’Halla, President and CEO for Eloquest Healthcare. “The BeneHold CHG adhesive technology delivers the combination of fluid management and sustained transparency with antimicrobial effect of chlorhexidine gluconate, offering clinicians a simple and innovative solution for post-op site management.”

The ReliaTect dressings will be available in two sizes (small and large) and designed to be ideal for various post-operative sites.

“BeneHold CHG adhesive technology adds value to post-operative dressings,” said Kirsten Newquist, general manager for Avery Dennison Medical. “The collaboration with Eloquest Healthcare brings together complementary resources, experience and expertise from each company. We look forward to working with Eloquest Healthcare to bring ReliaTect to market.”

Eloquest Healthcare and Avery Dennison Medical will showcase the new Eloquest Healthcare ReliaTect dressings in booth #3019 at the AORN Global Surgical Conference & Expo, April 2—4 in Boston, MA. To learn more about the Eloquest Healthcare ReliaTect post-operative dressings with CHG visit,


About Eloquest Healthcare

Eloquest Healthcare, Inc. is a wholly owned subsidiary of Ferndale Pharma Group, Inc. that is focused specifically on serving hospitals, their healthcare practitioners, and patients. Eloquest Healthcare helps deliver safer, more compassionate care by providing intuitive, cost-effective solutions that complement treatment protocols. More information can be found at


About Avery Dennison

Avery Dennison (NYSE:AVY) is a global leader in pressure-sensitive and functional materials and labeling solutions for the retail apparel market. The company’s applications and technologies are an integral part of products used in every major industry. With operations in more than 50 countries and more than 25,000 employees worldwide, Avery Dennison serves customers in the consumer packaging, graphical display, logistics, apparel, industrial and healthcare industries. Headquartered in Glendale, California, the company reported sales of $6.1 billion in 2016. Learn more




© 2016 Avery Dennison Corporation, All Rights Reserved.

Various trademarks and trade names are used herein and are the property of their respective owners.